The patients who received postoperative ghrelin therapy had a lower duration of SIRS than patients who received no ghrelin or a placebo (MD: − 2.72, 95% CI − 3.98, − 1.45, P = 0.0001). The gene discussed is GHRL; the disease is systemic inflammatory response syndrome.